News Archive
IDACIO® (adalimumab-aacf) Now Available in the United States
Fresenius Kabi announced today the immediate availability in the U.S. of its citrate-free adalimumab biosimilar IDACIO® (adalimumab-aacf) for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product, Humira® (adalimumab).
CMS grants Fresenius Kabi permanent, product-specific Q-Code for Stimufend® (pegfilgrastim-fpgk)
The approval of the adalimumab biosimilar, adalimumab-aacf, signals the beginning of Fresenius Kabi’s long-term dedication to biosimilars.
Stimufend® (pegfilgrastim-fpgk) Now Available in the United States
Fresenius Kabi announced today the immediate availability in the U.S. of Stimufend®(pegfilgrastim-fpgk), the company’s biosimilar to Neulasta® (pegfilgrastim), for use in patients at risk for febrile neutropenia
Biosimilar Adalimumab-aacf Gains FDA Approval, Marks Growing Interest in Biosimilar Development
The approval of the adalimumab biosimilar, adalimumab-aacf, signals the beginning of Fresenius Kabi’s long-term dedication to biosimilars.
